Peptide Companion
Peptide Companion
blend
Weight Management
Vial: 10 mg

How is Cagrilintide + Semaglutide (10 mg Blend) dosed and mixed?

Cagrilintide + Semaglutide (10 mg Blend) is a peptide blend research reference in the Weight Management category for a 10 mg vial. The reference mixing guide adds 3 mL of bacteriostatic water, giving a concentration of 3.33 mg/mL. The full reference schedule, supplies and cited studies are listed below; it is reference information, not a recommendation.

By Vincent Ceniceros · Published · Last updated

Cagrilintide + Semaglutide is a dual‑agonist combination blending an amylin analog (cagrilintide) with a GLP‑1 receptor agonist (Semaglutide). Clinical trials demonstrate superior weight reduction versus either agent alone, with the combination targeting complementary satiety pathways. This educational protocol presents a once‑weekly subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

Detailed protocol below.

Dosing Schedule
Week/PhaseDose per Peptide (mcg / mg)Units (mL)
Weeks 1–4250 mcg (0.25 mg) each15 units (0.15 mL)
Weeks 5–8500 mcg (0.50 mg) each30 units (0.30 mL)
Weeks 9–121000 mcg (1.0 mg) each60 units (0.60 mL)
Weeks 13–161700 mcg (1.7 mg) each102 units (1.02 mL)
Week 17+2400 mcg (2.4 mg) each144 units (1.44 mL)
Mixing & Quick Reference
Bacteriostatic water
3 mL
Concentration
3.33 mg/mL
  • •Reconstitute: Add 3.0 mL bacteriostatic water → ~ 3.33 mg/mL total (1.67 mg/mL each peptide).
  • •Typical weekly range: 0.25–2.4 mg of each peptide once weekly (gradual titration over 16+ weeks).
  • •Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 16.7 mcg each peptide on a U‑100 insulin syringe.
  • •Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days; avoid freeze–thaw cycles.
Supplies Needed
  • •Peptide Vials (Cagrilintide + Semaglutide, 10 mg blend each):
  • •Insulin Syringes (U‑100):
  • •Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each week.
Benefits
  • •Weight reduction: Phase 2 trials report mean body‑weight loss of ~15–17% at 32 weeks with the combination, exceeding Semaglutide monotherapy.
  • •Glycemic control: In type 2 diabetes, HbA1c reductions were observed alongside weight loss.
  • •GI tolerability: Nausea, vomiting, and diarrhea are the most common adverse events; gradual titration minimizes severity.
  • •Injection‑site reactions: Mild and transient in clinical reports.
How It Works

Cagrilintide is a long‑acting amylin analog that reduces appetite via central satiety pathways, while Semaglutide activates GLP‑1 receptors to enhance glucose‑dependent insulin secretion and suppress glucagon. The combination leverages complementary mechanisms: amylin primarily delays gastric emptying and signals satiety through the area postrema, while GLP‑1 enhances pancreatic β‑cell function and central appetite suppression. Clinical trials of the co‑administered regimen (CagriSema) show greater body‑weight reduction than either agent alone.

References and original studies

  • Lancet Diabetes Endocrinology (2024)

    Efficacy and safety of co‑administered once‑weekly cagrilintide 2.4 mg with Semaglutide 2.4 mg in type 2 diabetes: phase 2 trial

    View original study

  • Lancet (2021)

    Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant cagrilintide with Semaglutide 2.4 mg: phase 1b trial

    View original study

  • Lancet (2021)

    Once‑weekly cagrilintide for weight management: dose‑finding phase 2 trial in overweight/obesity

    View original study

  • StatPearls (2025)

    Semaglutide: pharmacology, indications, and clinical use overview

    View original study

  • Cureus (2024)

    Semaglutide: risks and benefits review (PMC)

    View original study

  • WHO (2010)

    Best practices for injection and related procedures (WHO toolkit)

    View original study

  • LibreTexts (2020)

    Intradermal and subcutaneous injections: clinical procedures

    View source

  • CDC (2024)

    Vaccine administration: subcutaneous injection technique

    View source

  • PubMed (2024)

    Cagrilintide‑Semaglutide in adults with overweight/obesity and type 2 diabetes

    View original study

  • ScienceDirect (2024)

    Efficacy and safety of CagriSema 2.4 mg + 2.4 mg in type 2 diabetes

    View source

  • PMC (2019)

    Subcutaneous drug injection: pharmacologic review

    View original study

About the author

Vincent Ceniceros

Vincent Ceniceros created Peptide Companion and publishes its Dosage Library. Each guide summarizes a reference protocol and links to the studies and sources it draws on.

Published · Last updated

Related guides

Work out the mixing math for any vial with the peptide reconstitution calculator, or browse the full Dosage Library.

Educational content adapted from peptidedosages.com. Not medical advice.